Results 11 to 20 of about 3,371 (214)
Therapeutics and Clinical Risk Management, 2013 Silvio Caccia, Roberto William Invernizzi, Alessandro Nobili, Luca Pasina IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy Abstract: Cariprazine is a potential antipsychotic awaiting approval from the US Food and Drug Administration ...
Roberto William Invernizzi +2 more
exaly +2 more sources
Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains [PDF]
PharmaceuticalsIntroduction: The introduction of the transdiagnostic approach in psychiatry shifts the focus from discrete diagnoses to shared symptoms across various disorders.
Agota Barabassy +5 more
doaj +2 more sources
Symptomatic Profile of Cariprazine in the Context of ICD-11 Domains for Schizophrenia: Review of Clinically Oriented Studies [PDF]
Consortium Psychiatricum, 2022 INTRODUCTION: One of the innovations in the ICD-11grouping "Schizophrenia and Other Primary Psychotic Disorders" is the implementation of six symptom domains intended to improve diagnostics and treatment of these mental conditions in clinical practice ...
Alexey Viktorovich Pavlichenko +1 more
doaj +1 more source
Cariprazine Use in Early Psychosis: Three Case Reports
Frontiers in Psychiatry, 2021 Objective: Cariprazine is a new atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia (1, 2) and for the treatment of manic or mixed episodes associated with bipolar I disorder (1).
Ricardo Coentre +5 more
doaj +1 more source
European Psychiatry, 2023 Introduction There is an increasing need to understand the effectiveness of novel medications in real-world context since despite being the gold standard, double-blind trials have their own limitations as well.
E. Rancans +3 more
doaj +1 more source
Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
Frontiers in Psychiatry, 2021 Bipolar disorder (BD) is chronic psychiatric disorder associated with significant impairment in psychosocial functioning and quality of life. Although current pharmacological treatments for BD have improved its clinical management, many patients do not ...
André Do +3 more
doaj +1 more source
Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
Consortium Psychiatricum, 2020 Background. Cariprazine is a new piperazine derivative atypical antipsychotic, like aripiprazole and brexpiprazole. It has been approved for treating schizophrenia in many countries and has recently been included on the List of Essential Medicines in ...
Aleksandr M. Reznik +3 more
doaj +1 more source
Hypersexuality during treatment with cariprazine in a patient with schizophrenia? A case report
BMC Psychiatry, 2023 Background Cariprazine is a third-generation antipsychotic with a unique mechanism of action. It functions as a partial agonist with high affinity for dopamine D2 and D3 and serotonin 5-HT1A receptors, an antagonist for 5-HT2A (moderate affinity) and 5 ...
Polona Rus Prelog +1 more
doaj +1 more source
Dosing Cariprazine Within and Beyond Clinical Trials : Recommendations for the Treatment of Schizophrenia [PDF]
, 2022 Publisher Copyright: Copyright © 2022 Rancans, Dombi and Barabássy.Although the optimal dosing of an antipsychotic medication is known to be essential in the long-term management of schizophrenia, in case of novel drugs such as cariprazine, determining ...
Barabássy, Ágota +2 more
core +1 more source
Nowe leki w psychiatrii – kariprazyna, lurazydon, esketamina [PDF]
, 2021 Introduction: Invariably, the search for an “ideal drug” in psychiatry has been going for years, one that is safe and effective, prevents relapse and shows the least possible side effects.
Masiak, Jolanta +9 more
core +2 more sources